Considering the proposed involvement of multiple pathophysiological mechanisms—such as activation of the TGF-β1 pathway, fibrotic responses, immune dysregulation, and remodeling of the tumor microenvironment—RCND may be best understood as a heterogeneous syndrome, which cannot be explained by a single etiology or clinical outcome. The gene discussed is TGFB1; the disease is neoplasm.